NAK MEDICAL LIMITED Filleted Accounts Cover |  |

| NAK MEDICAL LIMITED |
|  | Company No. 09284080 |  |
|  |  | Information for Filing with The Registrar |  |  |
|  |  | 31 October 2025 |  |  |

NAK MEDICAL LIMITED Directors Report Registrar |  |

The Director presents his report and the accounts for the year ended 31 October 2025.
Principal activities |  |  |  |  |
The principal activity of the company during the year under review was Providing Specialists Medical Practice Activities..
Director |  |  |  |  |
The Director who served at any time during the year was as follows:
N. Kapse |  |  |  |  |  |  |
The above report has been prepared in accordance with the provisions applicable to companies subject to the small companies regime as set out in Part 15 of the Companies Act 2006.
Signed on behalf of the board |  |  |  |
N. Kapse |  |  |  |  |  |
Director |  |  |  |  |  |
07 July 2026 |  |  |  |  |  |

NAK MEDICAL LIMITED Balance Sheet Registrar |  |

at | 31 October 2025 |  |  |  |  |  |  |
Company No. | 09284080 |  | Notes | 2025 |  |  |  | 2024
|  |  |  |  |  | £ |  |  |  | £
Current assets |  |  |  |  |  |  |
| Cash at bank and in hand |  |  | 564,028 |  |  |  | 528,612
|  |  |  |  |  | 564,028 |  |  |  | 528,612
Creditors: Amount falling due within one year | 5 | (19,856) |  |  |  | (28,784)
Net current assets |  |  | 544,172 |  |  |  | 499,828
Total assets less current liabilities |  |  | 544,172 |  |  |  | 499,828
Net assets |  |  | 544,172 |  |  |  | 499,828
Capital and reserves |  |  |  |  |  |  |
| Called up share capital |  |  | 2 |  |  |  | 2
| Profit and loss account |  | 7 | 544,170 |  |  |  | 499,826
Total equity |  |  | 544,172 |  |  |  | 499,828
These accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime of the Companies Act 2006.
For the year ended 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
As permitted by section 444 (5A)of the Companies Act 2006 the directors have not delivered to the Registrar a copy of the company's profit and loss account.
Approved by the board on 07 July 2026 and signed on its behalf by: |  |
N. Kapse |  |  |  |  |  |  |
Director |  |  |  |  |  |  |
07 July 2026 |  |  |  |  |  |  |  |

NAK MEDICAL LIMITED Notes to the Accounts Registrar |  |

for the year ended 31 October 2025 |  |  |  |  |  |  |  |

1 | General information |  |
| NAK MEDICAL LIMITED is a private company limited by shares and incorporated in England and Wales.
| Its registered number is: 09284080 |  |  |  |  |  |
| Its registered office is: |  |  |  |  |  |  |  |  |  |
| 30 Melrose Gardens |  |  |  |  |  |  |  |  |  |
| Edgware |  |  |  |  |  |  |  |  |  |
| Middlesex |  |  |  |  |  |  |  |  |  |
| HA8 5LN |  |  |  |  |  |
| The accounts have been prepared in accordance and comply with FRS 102 and Section 1A - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

2 | Accounting policies |  |  |  |  |  |  |  |

| Revenue recognition |  |  |  |  |  |  |  |
| The Company’s contracts with customers typically include a single performance obligation, being the delivery of provision of services. Revenue is recognised when that performance obligation is satisfied, which is when control passes to the customer.

| Taxation |  |  |  |  |  |
| Income tax expense represents the sum of the tax currently payable and deferred tax. The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the profit and loss account because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible timing differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Current or deferred tax for the year is recognised in profit or loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.

| Trade and other creditors |  |  |  |  |  |  |  |
| Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

| Provisions |  |  |  |  |  |  |  |
| Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation. Provisions are charged as an expense to the profit and loss account in the year that the Company becomes aware of the obligation, and are measured at the best estimate at balance sheet date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties. When payments are eventually made, they are charged to the provision carried in the balance sheet.

3 | Employees |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  | 2025 |  |  |  | 2024
|  |  |  |  |  |  |  |  |  | Number |  |  |  | Number
|  | The average monthly number of employees (including directors) during the year was: | 1 |  |  |  | 1

4 | Taxation |  |  |  |  |  |  |  |
|  | (a) Tax on profit on ordinary activities |  |  | 2025 |  |  |  | 2024
|  | The tax charge is made up as follows: |  |  |  | £ |  |  |  | £
|  | UK corporation tax |  |  |  |  |  |  |  |
|  | Charge for the period |  |  |  | 19,178 |  |  |  | 27,518
|  | Total corporation tax |  |  |  | 19,178 |  |  |  | 27,518
|  | Tax on profit on ordinary activities |  |  |  | 19,178 |  |  |  | 27,518
|  | (b) Factors affecting the total tax charge for the period |  |  |  |  |
|  | The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The differences are reconciled below:
|  | Higher |  |  |  |  |  |  |  | 2025 |  |  |  | 2024
|  | 19178 |  |  |  |  |  |  |  | £ |  |  |  | £
|  | Profit on ordinary activities before tax |  |  |  | 86,522 |  |  |  | 117,993
|  | Profit on ordinary activities multiplied by standard rate of corporation tax in the United Kingdom |  | - |  |  |  | -
|  | Expenses not deductible for tax purposes |  | 19,178 |  |  |  | 27,518
|  | Tax on profit on ordinary activities |  |  |  | 19,178 |  |  |  | 27,518

5 | Creditors: |  |  |  |  |  |  |  |
|  | amounts falling due within one year |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  | 2025 |  |  |  | 2024
|  |  |  |  |  |  |  |  |  | £ |  |  |  | £
|  | Taxes and social security |  |  |  | 19,208 |  |  |  | 27,548
|  | Loans from directors |  |  |  | 48 |  |  |  | 637
|  | Accruals and deferred income |  |  |  | 600 |  |  |  | 599
|  |  |  |  |  |  |  |  |  | 19,856 |  |  |  | 28,784

6 | Share Capital |  |  |  |  |  |  |  |
|  | Ordinary Share Capital

7 | Reserves |  |  |  |  |  |  |  |
|  | Profit and loss account - includes all current and prior period retained profits and losses.

8 | Dividends |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  | 2025 |  |  |  | 2024
|  |  |  |  |  |  |  |  |  | £ |  |  |  | £
|  | Dividends for the period: |  |  |  |  |  |  |  |
|  | Dividends paid in the period |  |  |  | 23,000 |  |  |  | 30,500
|  |  |  |  |  |  |  |  |  | 23,000 |  |  |  | 30,500
|  | Dividends by type: |  |  |  |  |  |  |  |
|  | Non-equity preference dividends |  |  |  | - |  |  |  | -
|  | Equity dividends |  |  |  | 23,000 |  |  |  | 30,500
|  |  |  |  |  |  |  |  |  | 23,000 |  |  |  | 30,500

NAK MEDICAL LIMITED 09284080 31 October 2025 01 November 2024 false 07 July 2026 BTCSoftware AP Solution 2026 14.1.19 14.1.19 true 09284080 2024-11-01 2025-10-31 09284080 2025-10-31 09284080 2024-10-31 09284080 core:WithinOneYear 2025-10-31 09284080 core:WithinOneYear 2024-10-31 09284080 core:ShareCapital 2025-10-31 09284080 core:ShareCapital 2024-10-31 09284080 core:RetainedEarningsAccumulatedLosses 2025-10-31 09284080 core:RetainedEarningsAccumulatedLosses 2024-10-31 09284080 countries:UnitedKingdom 2024-11-01 2025-10-31 09284080 bus:RegisteredOffice 2024-11-01 2025-10-31 09284080 2023-11-01 2024-10-31 09284080 core:RetainedEarningsAccumulatedLosses 2024-11-01 2025-10-31 09284080 bus:AllOrdinaryShares 2024-11-01 2025-10-31 09284080 2024-11-01 09284080 bus:SmallEntities 2024-11-01 2025-10-31 09284080 bus:FullAccounts 2024-11-01 2025-10-31 09284080 bus:AuditExempt-NoAccountantsReport 2024-11-01 2025-10-31 09284080 bus:Director1 2024-11-01 2025-10-31 09284080 bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 iso4217:GBP xbrli:pure